Immunocore Holdings plc ADR(IMCR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.35 | Insider Own | 0.96% | Shs Outstand | 51.5M | Perf Week | -10.14% |
| Market Cap | 1.73B | Forward P/E | - | EPS next Y | -834.44% | Insider Trans | - | Shs Float | 51.0M | Perf Month | -1.76% |
| Enterprise Value | 1.28B | PEG | - | EPS next Q | -0.12 | Inst Own | 100.57% | Short Float | 15.48% | Perf Quarter | 20.36% |
| Income | -0.02B | P/S | 4.02 | EPS this Y | 90.99% | Inst Trans | -0.73% | Short Ratio | 15.38 | Perf Half Y | 3.26% |
| Sales | 0.43B | P/B | 4.14 | EPS next 5Y | - | ROA | -1.64% | Short Interest | 7.90M | Perf YTD | -3.26% |
| Book/sh | 8.11 | P/C | 1.96 | EPS past 3/5Y | - | ROE | -4.47% | 52W High | -17.52% ($40.71) | Perf Year | -7.76% |
| Cash/sh | 17.09 | P/FCF | - | Sales past 3/5Y | 31.32% 59.68% | ROIC | -2.12% | 52W Low | 21.87% ($27.56) | Perf 3Y | -39.89% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | 98.06% | Volatility(W/M) | 3.35% 3.24% | Perf 5Y | 4.84% |
| Dividend TTM | - | EV/Sales | 2.99 | Sales Y/Y TTM | 20.19% | Oper. Margin | -5.24% | ATR (14) | 1.24 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.44 | EPS Q/Q | 92.33% | Profit Margin | -4.2% | RSI (14) | 38.31 | Recom | 1.6 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.47 | Sales Q/Q | 17.1% | SMA20 | -6.94% ($36.08) | Beta | 0.8 | Target Price | $63.85 |
| Payout | - | Debt/Eq | 1.04 | Earnings | 2026/8/6 | SMA50 | -3.14% ($34.67) | Rel Volume | 0.43 | Prev Close | $34.47 |
| Employees | 524 | LT Debt/Eq | 1.03 | EPS/Sales Surpr. | -306.19% 5.03% | SMA200 | 2.67% ($32.71) | Avg Volume(3M) | 0.51M | Price | $33.58 |
| IPO | 2021/2/5 | Option/Short | Yes/Yes | Trades | 2786 | Volume | 221,820 | Change | -2.58% |
Company
IMCR is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Immunocore Holdings is a commercial-stage biotech company developing oncology, infectious disease, and autoimmune therapies based on its proprietary ImmTAX (ImmTAC) T-cell receptor bispecific antibody platform. Its first approved drug, KIMMTRAK (tebentafusp), is a treatment for metastatic uveal melanoma and is marketed in the United States and Europe, forming the company's current revenue base. Headquartered in the US and UK, the company is expanding its global clinical pipeline.
Over the past 1 year, roughly in the middle
18% below its 1-year high.
IMCR has weak earning power
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +91.0% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Long-term returns are close to the market
Would have changed by -39.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 100.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
BBP 0.01%
SBIO 0.01%
CANC 0.01%
TMED 0.00%
LYTE 0.00%It ranks #4 in the industry
Based on market cap of $2B.
IMCR $2B PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is IMCR?
IMCR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IMCR?
The market cap of IMCR is approximately $1.7B, ranking 2,223 within its sector.
What is the 52-week high and low for IMCR?
IMCR has recorded a 52-week high of $40.71 and a low of $27.56.
